Hvivo logo

HVO - Hvivo Share Price

16.5p -0.9  -5.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Micro Cap
Market Cap £13.8m
Enterprise Value £13.2m
Revenue £12.1m
Position in Universe th / 1834
Bullish
Bearish
Unlock HVO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HVO Revenue Unlock HVO Revenue

Net Income

HVO Net Income Unlock HVO Revenue

Normalised EPS

HVO Normalised EPS Unlock HVO Revenue

PE Ratio Range

HVO PE Ratio Range Unlock HVO Revenue

Dividend Yield Range

HVO Dividend Yield Range Unlock HVO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HVO EPS Forecasts Unlock HVO Revenue
Profile Summary

hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated March 27, 2012
Public Since May 3, 2012
No. of Shareholders: n/a
No. of Employees: 139
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange London Stock Exchange
Shares in Issue 83,664,276
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HVO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to HVO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.